Wim Dokter
Chief Scientific Officer Byondis B.V.
Seminars
Wednesday 14th October 2026
Spotlighting Comprehensive Preclinical Development of Antifolate ADCs to Enter IND Phase for a Novel Drug-Linker Mechanism
11:00 am
- Presenting development of a novel antifolate linker-payload platform, leveraging a toxin class with a clinically validated mechanism of action
- Exploring in vitro and in vivo preclinical development and physicochemical properties of frontrunner antifolate ADC program
- Laying out pharmacology studies and dose range finding investigation in the lead up to antifolate ADC IND studies
Monday 12th October 2026
Introducing ByonGuard: Conditional Activation Technology that Improves the Safety Profile & Therapeutic Index of ADCs
10:30 am
- Demonstrating rationale to develop conditionally active ADCs to overcome challenges with target mediated toxicity and improve therapeutic index
- Laying out ADC masking mechanism leveraging steric masking nanobody peptide activated by a variety of proteases in the tumor
- Highlighting development of ADCs leveraging masking technology including preclinical efficacy and safety profiles
